Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)

Actinium Pharmaceuticals, Inc.

Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.
Iomab-B is a targeted radiotherapy conditioning regimen prior to bone marrow transplant; compared to conventional care with intent to transplant.
Company to submit Biologics License Application (BLA) to FDA for approval of Iomab-B; additional SIERRA data expected by year-end 2022.
CEO Sandesh Seth calls it a significant milestone; CMO Avinash Desai highlights statistical significance and increased access to BMT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.